Reduction of draining tunnels sustained to three years: Of patients who had at least one draining tunnel at baseline, 48.2% had none at one year, and 62.9% at three years* – indicating sustained ...

Over half of patients had no draining tunnels (DTs) at two years: In 425 hidradenitis suppurativa (HS) patients with ≥1 DTs at baseline, 55.7% (195/350) had no DTs at two years of treatment. ≠ DTs are ...

ATLANTA, March 8, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies examining ...

Citryll has dosed the first patient in the Phase IIa Citylights clinical trial of the monoclonal antibody, CIT-013, for moderate-to-severe hidradenitis suppurativa (HS), a chronic autoimmune disease.

Learning to manage hidradenitis suppurativa can be an ongoing process. The chronic skin condition causes painful lumps under the skin, especially in the armpits, groin, and under the breasts, ...

Brussels (Belgium), March 7, 2025 – 14:00 (CET) – UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX ® (bimekizumab-bkzx) in moderate to ...

Over half of patients had no draining tunnels (DTs) at two years: In 425 hidradenitis suppurativa (HS) patients with =1 DTs at baseline, 55.7% (195/350) had no DTs at two years of treatment.? DTs are ...